Outcomes for 24 patients with metastatic MITF family translocation renal cell carcinoma treated with an immune checkpoint inhibitor (ICI)

Patient number	Sex	Age at diagnosis, years	Translocation type	TNM at diagnosis	FISH analysis	Karnofsky score	Heng score (IDMC criteria)	First treatment line	Response to 1st line	PFS (mo)	Immunotherapy treatment	ICI line	Response to ICI	Duration of response (mo)	Deseased	Survival (mo)
1	F	25	TFE B	T3N2M1	available	100	2	Sunitinib	PD	2	Ipilimumab	4	PR	9.0	no	40
2	F	3	TFE 3+	TxN0M0	available	100	1	Sunitinib	PD	1	Ipilimumab	5	PD	2.5	yes	23.5
3	F	13.7	TFE 3+	T2N + M+	available	60	3	Pazopanib	PR	4	Ipilimumab	3	PD	2,0	yes	20.7
4	F	10	TFE 3+	TxNxM0	available	< 80	1	Everolimus	PD	4.4	Atezolizumab	2	PD	0.8	no	19
5	F	35.5	TFE 3+	T2bN1Mx	available	100	4	Sunitinib	PD	4.4	Nivolumab	5	PD	1.0	yes	24.5
6	M	22	TFE 3+	pT1bNxM0	available	100	1	Sunitinib	PD	1	Nivolumab	2	PR	8.3	no	17
7	F	26.7	TFE 3+	pT1bNxMxR1	available	100	0	Sunitinib	PD	4	Nivolumab	3	PD	2.4	no	25
8	M	60.7	TFE B	pT3cN0M1R1	available	100	1	Sunitinib	PD	3.1	Nivolumab	3	PD	2.5	yes	19.5
9	F	35	TFE 3+	pT3aN1Mx	available	100	1	Sunitinib	PD	2.7	Nivolumab	2	PD	1.0	yes	9.6
10	M	41.9	TFE 3+	pT3bN1Mx	no	90	1	Pazopanib	PD	1.2	Nivolumab	2	PD	1.4	yes	8.5
11	F	35.1	TFE 3+	T3cN0M0	available	90	1	High dose IL-2	PD	0.1	MEDI4736 + Tremelimumab	4	PD	2.4	yes	16.9
12	F	16.1	TFE 3+	T1aN1M1	available	70	2	Sunitinib +nivolumab	SD	3.2	Sunitinib +nivolumab	1	PR	3.2	yes	7.6
13	F	79.5	TFE 3+	T3aN0M0	available	60	1	Temsirolimus	SD	1.2	Nivolumab	5	PD	1.0	yes	17.3
14	F	54	TFE 3+	T2aN0M1	available	80	2	Pazopanib	PR	17.2	Nivolumab	2	SD	15.4	no	84.6
15	F	42.8	TFE 3+	T3N + M+	available	100	1	Sunitinib	SD	22	Nivolumab	4	PD	9.0	no	59
16	M	32	TFE B	T3bN0M1	available	80	0	Sunitinib	PD	1	Nivolumab	2	SD	14	no	25
17	F	29.4	TFE 3+	T4N1M1	available	80	5	Pazopanib	SD	3	Nivolumab	2	PD	3	no	4
18	F	26.7	TFE 3+	NA	no	90	2	Sunitinib	SD	15	pembro +41BB agonist	3	PR	30	yes	60
19	F	49	TFE 3+	pT4pN1pM1	no	NA	1	Sunitinib	PD	3	Nivolumab	2	SD	8.5	yes	19
20	F	43	TFE 3+	T3bN0M0	available	90	1	Sunitinib	PD	1.5	Nivolumab	3	PD	1	yes	8
21	F	63	TFE 3+	pT3aNxMx	available	90	1	Sunitinib	PD	6	Nivolumab	5	PD	2	yes	24
22	F	48.2	TFE 3+	T3NxM1	available	70	3	Sunitinib	PD	3	Nivolumab	2	PD	2	no	5
23	F	45	TFE 3+	pT3aNxM1R1	available	80	1	Sunitinib	PD	2	Nivolumab	2	PD	3	yes	9
24	F	24	TFE 3+	pT2bN1	available	NA	1	Sorafenib	SD	12	Nivolumab	3	PD	4	no	70

PR: partial response; SD: stable disease; PD: progressive disease